Diffuse large B-cell lymphoma (DLBCL) Anti-CD19 ADC: Loncatuximab Tesirine Anti-CD19 CAR T cell: Preferred for relapsed/refractory DLBCL if relapsed <1 year. Tisag enlecleucel (tisa-cel) Axicabtagene ciloleucel (axi-cel) Lisocabtagene maraleucel (liso-cel) Brexucabtagene autoleucel (bre xu-cel) Anti-CD19 mAb: Tafasitamab Anti-CD79b ADC ( Antibody–Drug Conjugate ): Polatuzumab vedotin CD20 x CD3 Bispecific Ab: Engineered antibody that simultaneously binds to CD20 on B cells an